Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Discoid Lupus Erythematosus
Interventions
DRUG

Ruxolitinib 1.5% cream

Topical application of Ruxolitinib 1.5% cream

PROCEDURE

Application without occlusion in Area 1

Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 1.

PROCEDURE

Application under occlusion at night in Area 2

Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 2.

PROCEDURE

Application under occlusion at night in Area 1

Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 1.

PROCEDURE

Application without occlusion in Area 2

Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 2.

Trial Locations (2)

E3B 1G9

RECRUITING

INNO-6051 Site 03, Fredericton

H2X 2V1

RECRUITING

Innovaderm Research Inc., Montreal

Sponsors
All Listed Sponsors
lead

Innovaderm Research Inc.

OTHER